All In Biotech

NDA 018608 · Hospira

Plegisol In Plastic Container

Calcium Chloride, Magnesium Chloride, Potassium Chloride, Sodium Chloride · Perfusion, Cardiac

Priority review

Last checked: Nov 20, 2026Latest source record: Dec 16, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Feb 26, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

16

11 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 27, 2026.

INDICATIONS AND USAGE Plegisol (Cardioplegic Solution) when suitably buffered in combination with ischemia and hypothermia is used to induce cardiac arrest during open heart surgery.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 26, 1982 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • PLEGISOL IN PLASTIC CONTAINER · CALCIUM CHLORIDE 17.6MG/100ML; MAGNESIUM CHLORIDE 325.3MG/100ML; POTASSIUM CHLORIDE 119.3MG/100ML; SODIUM CHLORIDE 643MG/100ML · SOLUTION, PERFUSION, CARDIAC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5
  • cerebrovascular accident3
  • renal failure3
  • injury2
  • multiple sclerosis2
  • peripheral vascular disorder2
  • renal injury2
  • acute kidney injury1
  • acute respiratory failure1
  • anaemia1
  • anaphylactic reaction1
  • anxiety1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20052
20113
20122
20131
20193
20223
20251

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,091 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.